title: Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia.
authors.forename: O G
authors.initials: OG
authors.lastname: Ottmann
authors.forename: R A
authors.initials: RA
authors.lastname: Larson
authors.forename: H M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: P D
authors.initials: PD
authors.lastname: le Coutre
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
authors.forename: D W
authors.initials: DW
authors.lastname: Kim
authors.forename: X
authors.initials: X
authors.lastname: Fan
authors.forename: S
authors.initials: S
authors.lastname: Novick
authors.forename: F J
authors.initials: FJ
authors.lastname: Giles
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D011505:Protein-Tyrosine Kinases; C498826:nilotinib